Cited by

• Long-term outcomes and role of chemotherapy in adults with newly diagnosed medulloblastoma.

  Call JA, Naik M, Rodriguez FJ, Giannini C, Wu W, Buckner JC, Parney IF, Laack NN. Call JA, et al. Am J Clin Oncol. 2014 Feb;37(1):1-7. doi: 10.1097/COC.0b013e31826b9cf0. Am J Clin Oncol. 2014. PMID: 23111362 Free PMC article.
• Epigenetic Silencing of DKK3 in medulloblastoma.

  Valdora F, Banelli B, Stigliani S, Pfister SM, Moretti S, Kool M, Remke M, Bai AH, Brigati C, Hielscher T, Romani M, Servidei T, Zollo M, Cinalli G, Oberthuer A, Tonini GP, Coco S. Valdora F, et al. Int J Mol Sci. 2013 Apr 8;14(4):7492-505. doi: 10.3390/ijms14047492. Int J Mol Sci. 2013. PMID: 23567267 Free PMC article.
• Preoperative Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio are Associated with the Prognosis of Group 3 and Group 4 Medulloblastoma.

  Li K, Duan WC, Zhao HB, Wang L, Wang WW, Zhan YB, Sun T, Zhang FJ, Yu B, Bai YH, Wang YM, Ji YC, Zhou JQ, Liu XZ, Zhang ZF, Zhang ZY. Li K, et al. Sci Rep. 2019 Sep 13;9(1):13239. doi: 10.1038/s41598-019-49733-6. Sci Rep. 2019. PMID: 31519974 Free PMC article.
• Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density.

  Miralbell R, Tolnay M, Bieri S, Probst A, Sappino AP, Berchtold W, Pepper MS, Pizzolato G. Miralbell R, et al. J Neurooncol. 1999;45(2):103-10. doi: 10.1023/a:1006330324991. J Neurooncol. 1999. PMID: 10778725
• Review of 20 years of adult medulloblastoma treatment: Chemotherapy prescription trends and survival.

  Sherwood M, Climans S, Ramos R, Laperriere NJ, Gao AF, Millar BA, Shultz DB, Tsang DS, Mason WP. Sherwood M, et al. Neurooncol Pract. 2022 Sep 18;10(2):186-194. doi: 10.1093/nop/npac074. eCollection 2023 Apr. Neurooncol Pract. 2022. PMID: 36970168 Free PMC article.